A Phase I, Open-Label, Multicenter, Dose-Escalation And Cohort-Expansion Study Of IMM47 In Subjects With Advanced Solid Tumors
Latest Information Update: 06 Oct 2023
At a glance
- Drugs IMM 47 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors ImmuneOnco Biopharma
Most Recent Events
- 02 Oct 2023 Status changed from not yet recruiting to recruiting.
- 16 Aug 2023 New trial record